Life-Science Biotech Growth Strategies: Cultivation and Regulation In Today's Global Marketplace - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Life-Science Biotech Growth Strategies: Cultivation and Regulation In Today's Global Marketplace
To effectively grow in the biotech industry, companies must develop multiphase plans that focus on regulation and efficiency.


Pharmaceutical Technology


Scale-up. Learning how to effectively scale up is a crucial aspect of life-science biotechnology company development. Due to high demand projections in this area, industry professionals must be prepared to adapt. Scale-up acceleration depends largely on the ability to define and control processes that produce similar products as those obtained at small scale. For a smooth transition to occur, industrial engineers assist in the implementation of creating high-tech production processes, while scientists take care of late-stage development, ensuring smooth implementation of final phase (III and IV) clinical trials as well as compliance with regulatory demands.

Partnerships. Along the biotechnology company cultivation path, industry professionals must form partnerships that help them attain their development goals. Companies such as Burrill & Company and LSGPA assist life science companies in the development of these strategic partnerships that provide access to resources, marketing tools, funding, intellectual property licensing, and technologies or other alliances necessary for realizing their business plans.

Regulation. Life-science biotechnology companies must consider strategies for streamlining FDA approval, reimbursement, clinical trial design, product liability, and insurance concerns throughout the entire growth process. This will not only encourage efficiency in terms of commercialization, but it will also help with safety issues and decrease overall liabilities.

Conclusion

The future of life-sciences biotechnology companies in the 21st century is promising. Modern science and medicine in Karl Ereky's "biotechnology age" continue to flourish and revolutionize the manner in which the global community thinks about the healthcare industry. Over the next 10 years, we will undoubtedly continue to see product growth in this area as well as advancements in how these technologies develop from start to finish. INTERPHEX will continue to be a resource and reflect as well as represent cutting-edge thought leaders and technology for the pharmaceutical and biotech markets.

RJ Palermo is the event director for INTERPHEX, tel. 203.840.5924,

Reference

1. http://Biotechnology.Reference.com/. Wikipedia, the free encyclopedia. http:// http://www.reference.com/browse/wiki/Biotechnology (accessed: Jan. 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here